A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Open Access
- 28 February 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Chemical Biology
- Vol. 6 (4), 291-299
- https://doi.org/10.1038/nchembio.332
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- c-Src and cooperating partners in human cancerCancer Cell, 2004
- Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer CellsCancer Research, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing AktCancer Research, 2004
- A renaissance for SRCNature Reviews Cancer, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85αOnline Journal of Public Health Informatics, 1995
- Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family KinasesJBIC Journal of Biological Inorganic Chemistry, 1994
- A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis.Proceedings of the National Academy of Sciences of the United States of America, 1994
- High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains.Proceedings of the National Academy of Sciences of the United States of America, 1992